Data gathered: December 21
AI Stock Analysis - Ocugen (OCGN)
Analysis generated June 7, 2024. Powered by Chat GPT.
Ocugen, Inc. (NASDAQ: OCGN) is a clinical-stage biopharmaceutical company with a focus on discovering, developing, and commercializing transformative therapies designed to improve global health. The company is known for its commitment to addressing unmet medical needs with innovative solutions. Ocugen is particularly involved in gene therapy for retinal diseases and has recently expanded its portfolio to include a COVID-19 vaccine candidate through a partnership with Bharat Biotech.
Stock Alerts - Ocugen (OCGN)
 |
Ocugen | December 18 Price is down by -9.9% in the last 24h. |
|
Ocugen | December 9 Price is up by 5.2% in the last 24h. |
|
Ocugen | December 3 Insider Alert: Fernandes Prabhavathi is buying shares |
|
Ocugen | December 2 Price is down by -5.2% in the last 24h. |
Alternative Data for Ocugen
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 2 | Sign up | Sign up | Sign up |
| Sentiment | 91 | Sign up | Sign up | Sign up |
| Webpage traffic | 10,000 | Sign up | Sign up | Sign up |
| Employee Rating | 54 | Sign up | Sign up | Sign up |
| Google Trends | 38 | Sign up | Sign up | Sign up |
| Patents | 4 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 87 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 154,628 | Sign up | Sign up | Sign up |
| Twitter Followers | 51,786 | Sign up | Sign up | Sign up |
| Twitter Mentions | 31 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | 29 | Sign up | Sign up | Sign up |
| Lobbying Cost | $10,000 | Sign up | Sign up | Sign up |
| Business Outlook | 29 | Sign up | Sign up | Sign up |
| Linkedin Employees | 77 | Sign up | Sign up | Sign up |
About Ocugen
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat blindness diseases. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many”.
| Price | $0.77 |
| Target Price | Sign up |
| Volume | 21,290,000 |
| Market Cap | $224M |
| Year Range | $0.75 - $1.98 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease SummitDecember 11 - GlobeNewswire |
|
Ocugen CEO to Present at NobleCon20, Noble Capital Markets 20th Annual Emerging Growth Equity ConferenceNovember 27 - Finnhub |
|
Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity ConferenceNovember 27 - GlobeNewswire |
|
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt DiseaseNovember 20 - Finnhub |
|
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt DiseaseNovember 20 - GlobeNewswire |
|
Ocugen Announces Compelling Preliminary Data for OCU410-a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular DegenerationNovember 19 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 1.1M | 6.3M | -5.1M | -13M | -13M | 0.000 |
| Q2 '24 | 1.1M | 7.7M | -6.5M | -15M | -15M | -0.040 |
| Q1 '24 | 1M | 6.6M | -5.6M | -12M | -12M | -0.050 |
| Q4 '23 | 1.4M | 5.3M | 700,000 | -11M | -11M | -0.030 |
| Q3 '23 | 3.7M | 9.1M | -9.1M | -12M | -15M | -0.060 |
Insider Transactions View All
| Fernandes Prabhavathi filed to buy 10,000 shares at $0.9. December 2 '24 |
| Castillo Kirsten filed to buy 75,000 shares at $0.9. November 26 '24 |
| Zhang Junge filed to buy 1,077,182 shares at $0.5. June 16 '23 |
| Musunuri Shankar filed to sell 2,190,073 shares at $1.1. February 17 '23 |
| Musunuri Shankar filed to sell 2,227,950 shares at $1.3. January 19 '23 |
Similar companies
Read more about Ocugen (OCGN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Ocugen?
The Market Cap of Ocugen is $224M.
What is the current stock price of Ocugen?
Currently, the price of one share of Ocugen stock is $0.77.
How can I analyze the OCGN stock price chart for investment decisions?
The OCGN stock price chart above provides a comprehensive visual representation of Ocugen's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Ocugen shares. Our platform offers an up-to-date OCGN stock price chart, along with technical data analysis and alternative data insights.
Does OCGN offer dividends to its shareholders?
As of our latest update, Ocugen (OCGN) does not offer dividends to its shareholders. Investors interested in Ocugen should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Ocugen?
Some of the similar stocks of Ocugen are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.